AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04701190
Drug: Infusion dosage: 0.075 microgram/kg/minute infusion
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nfusion dosage: 0.075 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus.
Trial: NCT04816890
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous administration of insulin lispro in combination with a basal insulin.
Trial: NCT05539924
Drug: Pregabalin 150mg gabapentin 400mg
RxNorm normalized name: pregabalin 150 MG
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral administration
Trial: NCT06278766
Drug: ABBV-552
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT04978181
Drug: Alteplase Injection
RxNorm normalized name: alteplase Injection
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: thrombolytic therapy for acute ischemic stroke in time window
Trial: NCT06362317
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240mg, intravenous infusion every 3 weeks until disease progression or occurrence of intolerable toxicity.
Trial: NCT06362317
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: When the body weight is ≥60 kg, the dosage of Lenvatinib is 12mg qd, when body weight \< 60kg the dosage is 8mg qd.
Trial: NCT05723874
Drug: BI 425809
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 425809
Trial: NCT05723874
Drug: bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bosentan
Trial: NCT05818306
Drug: BL-001
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live biological product BL-001
Trial: NCT05337657
Drug: GB491+Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart
Trial: NCT06505824
Drug: BL-M14D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT00373906
Drug: Bortezomib (Velcade)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06434090
Drug: Liposomal irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Liposomal irinotecan will be given biweekly at a dose from 70mg/m2 to 90mg/m2.
Trial: NCT06434090
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab will be given biweekly at a dose of 5mg/m2
Trial: NCT06066606
Drug: Vilanterol and Fluticasone Furoate (low dose)
RxNorm normalized name: fluticasone furoate / vilanterol Inhalant Product
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants are administered 25 µg of vilanterol + fluticasone furoate
Trial: NCT06066606
Drug: Vilanterol and Fluticasone Furoate (high dose)
RxNorm normalized name: fluticasone furoate / vilanterol Inhalant Product
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants are administered 100 µg of vilanterol + fluticasone furoate
Trial: NCT04867551
Drug: KDT-3594
RxNorm normalized name: KDT-3594
DrugBank: KDT-3594 (DB17085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, dose titration
Trial: NCT05549297
Drug: Tebentafusp
RxNorm normalized name: Tebentafusp
DrugBank: Tebentafusp (DB15283)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Soluble gp100-specific T cell receptor with anti-CD3 scFV
Trial: NCT05549297
Drug: Tebentafusp with Pembrolizumab
RxNorm normalized name: Tebentafusp
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with pembrolizumab
Trial: NCT05481411
Drug: Olpasiran
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05515770
Drug: Cabotegravir Injection
RxNorm normalized name: cabotegravir Injection
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long action cabotegravir injection
Trial: NCT04689217
Drug: intrathecal drug injection
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~The patients will be divided equally into 3 groups according to the additive (fentanyl, nalbuphine or placebo), and all patients will receive the local anesthetic dose of 0.5% heavy bupivacaine according to weight and height
Trial: NCT04066751
Drug: Ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg
Trial: NCT04989322
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg Q3W
Trial: NCT04989322
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg daily
Trial: NCT04989322
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m2 Q3W
Trial: NCT04989322
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC5 Q3W
Trial: NCT05825235
Drug: Pramipexole
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 months of treatment with add-on Pramipexole
Trial: NCT06298188
Drug: Risankizumab
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risankizumab
Trial: NCT06263816
Drug: Experimental group: Patients will be treated with carvedilol.
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive the number of pills of carvedilol corresponding to the dose determined during the titration period (either one pill of 6.25 mg in the morning or 1 pill of 6.25 mg twice a day, 1 in the morning and 1 in the evening.
Trial: NCT04729296
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For participants ≥45 kg, 50 mg of golimumab will be administered subcutaneously For participants \<45 kg, the dose of golimumab is 30 mg/m2 to maximum of 50 mg
Trial: NCT04556279
Drug: Aldosterone Antagonist
RxNorm normalized name: Aldosterone antagonists
DrugBank: Aldosterone (DB04630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment of primary hyperaldosteronism.
Trial: NCT04990219
Drug: Lu AG06466
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AG06466 - capsule
Trial: NCT05061524
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection of Omalizumab
Trial: NCT04771273
Drug: Survodutide
RxNorm normalized name: Survodutide
DrugBank: Survodutide (DB18989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survodutide
Trial: NCT05609578
Drug: Adagrasib oral dose of 400 mg twice daily tablets
RxNorm normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose of 400 mg twice daily tablets
Trial: NCT05096884
Drug: Metoprolol Succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum dose of 400 mg po daily.
Trial: NCT01869803
Drug: gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT04977960
Drug: Potassium Canrenoate
RxNorm normalized name: Potassium canrenoate
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: potassium canrenoate for 7 days in addition to maximal medical treatment
Trial: NCT06006091
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different endothelial preparations according to groups, see arm descriptions for details
Trial: NCT04853719
Drug: Rivaroxaban 2.5 Mg Oral Tablet
RxNorm normalized name: rivaroxaban 2.5 MG Oral Tablet
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral anticoagulants plus antiplatelet agent
Trial: NCT04838041
Drug: Asciminib 40 MG
RxNorm normalized name: asciminib 40 MG
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40 mg by mouth (PO) when used with imatinib.
Trial: NCT04838041
Drug: Asciminib 40 MG Twice Daily
RxNorm normalized name: asciminib 40 MG
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40 mg twice daily when used with nilotinib.
Trial: NCT04838041
Drug: Asciminib 80 MG daily
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 80 mg daily when used with dasatinib.
Trial: NCT04838041
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum dose of 400 mg PO once daily.
Trial: NCT04838041
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maximum dose of 300 mg twice daily.
Trial: NCT04838041
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum dose of 100 mg PO once daily.
Trial: NCT02050009
Drug: metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02050009
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02050009
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00002404
Drug: Valacyclovir hydrochloride
RxNorm normalized name: Valacyclovir Hydrochloride
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04259060
Drug: Hydroxocobalamin with Butyrate
RxNorm normalized name: Hydroxocobalamin
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In phase 1, patients will take hydroxocobalamin at 1g daily for four weeks. This will be in the form of 1 500mg capsule twice a day. Butyrate will be 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, the dose of hydroxocobalamin will be increased to 2g daily (1g twice a day) for four weeks pending FDA approval. Butyrate will remain at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day. Patients will undergo flexible sigmoidoscopy at baseline and at week four in phase 2.
Trial: NCT04259060
Drug: Placebo with Butyrate
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In phase 1, patients will take 1 placebo capsule twice a day. Butyrate will be taken at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, patients will take 2 placebo capsules twice a day, along with butyrate at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.
Trial: NCT06141577
Drug: UI059
RxNorm normalized name: Ulimorelin
DrugBank: Ulimorelin (DB12128)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take UI059 1cap/day for 7 days
Trial: NCT04820621
Drug: Runcaciguat (BAY1101042)
RxNorm normalized name: Runcaciguat
DrugBank: Runcaciguat (DB16700)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as 1 x 15 mg modified release \[MR\] tablet
Trial: NCT06477926
Drug: ABBV-668 IR
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Oral Capsule
Trial: NCT06477926
Drug: ABBV-668 ER
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Oral Tablets
Trial: NCT02929303
Drug: Omegaven IV lipid emulsion
RxNorm normalized name: propofol lipid emulsion
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy is started at a dose of 1 gm/kg/day over 12 hrs. Omegaven may be infused via a central or peripheral IV. If additional fat calories are needed they will be provided by the enteral route.
Trial: NCT06512831
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Those with risk factors were recommended a 6-month prophylaxis regimen, consisting of INH (300 mg/d) and pyridoxine (10 mg/d to prevent INH-related neurotoxicity).
Trial: NCT05185284
Drug: Favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 400 mg, lyophilizate for preparation of concentrate for solution for infusion
Trial: NCT05185284
Drug: Favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 200 mg coated tablets
Trial: NCT05185284
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg, lyophilizate for preparation of concentrate for solution for infusion
Trial: NCT04338165
Drug: Evolocumab 140 MG/ML [Repatha]
RxNorm normalized name: evolocumab 140 MG/ML [Repatha]
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 injections of evolocumab 140 milligrams performed within 30 minutes and self-administered (subcutaneously in the abdomen, thigh, or upper arm)
Trial: NCT04925947
Drug: KN046
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: KN046 will be given intravenously at 5 mg/kg every 2 weeks. A cycle is defined as 2 treatments (28 days). Treatment will be given until progression, excessive toxicity, or up to two years.
Trial: NCT06058884
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following the guidelines set forth by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
Trial: NCT05383716
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year.
Trial: NCT05406440
Drug: MK-8189
RxNorm normalized name: MK-8189
DrugBank: MK-8189 (DB19153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.
Trial: NCT04751318
Drug: Duloxetine 60mg Test Drug Enteric Coated Granules
RxNorm normalized name: duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational Medicinal Product
Trial: NCT04751318
Drug: Duloxetine 60mg Reference Product Enteric Coated Granules
RxNorm normalized name: duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cymbalta (Eli Lilly)
Trial: NCT06478043
Drug: ivonescimab
RxNorm normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg, IV, D1, Q3W
Trial: NCT06478043
Drug: irinotecan liposome
RxNorm normalized name: Irinotecan liposome
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 56.5mg/m\^2, IV, D1, Q2W
Trial: NCT06117904
Drug: MEBO ointment
DrugBank: Formebolone (DB01569)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group included twenty-five patients given Mebo ointment in combination with the symptomatic therapy 3 times daily for 7 weeks
Trial: NCT06706219
Drug: Sacituzumab tirumotecan plus pembrolizumab
RxNorm normalized name: sacituzumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants meeting the inclusion criteria will receive pembrolizumab 200 mg IV on D1, Q3W + SKB264 4mg/kg IV on D1, D15 and D29，Q2W for 12 weeks as induction therapy.~Subjects who receive radical radiotherapy will undergo 8 cycles of pembrolizumab 200 mg IV on D1, Q3W; For those receiving surgical treatment, pembrolizumab is selected for adjuvant therapy for pCR patients, and SKB264 combination with pembrolizumab is selected non-PCR patients.
Trial: NCT06726421
Drug: axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard systemic therapy are targeted agents or their combination with immunotherapy recommended by guidelines. This may include axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, etc.
Trial: NCT06725485
Drug: Low-Dose Lidocaine
RxNorm normalized name: ethinyl estradiol
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose lidocaine infusion 10-30 mcg/kg/min administered within 1 hour of ICU admission.
Trial: NCT05991895
Drug: Iruplinalkib
RxNorm normalized name: Iruplinalkib
DrugBank: Iruplinalkib (DB17494)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iruplinalkib is administered orally with approximately fixed dosing times each day. The recommended dosage is once daily, on an empty stomach or with food, at 60 mg per dose for the first 1 to 7 days. If tolerated, the dosage is increased to 180 mg per dose starting from the 8th day.
Trial: NCT06453356
Drug: Zavegepant 10mg
RxNorm normalized name: ZAVEGEPANT 10MG/SPRAY NASAL SOLN
DrugBank: Zavegepant (DB15688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intransal spray 10mg
Trial: NCT04756401
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04756401
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04756401
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04858425
Drug: Niclosamide
RxNorm normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niclosamide tablets 400 mg 3 times daily for 14 days
Trial: NCT05161403
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~use of this natural substance is a simple and cost-effective technique and is easily tolerated by children.
Trial: NCT00002146
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002146
Drug: Foscarnet sodium
RxNorm normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05909943
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with ruxolitinib will be initiated in an initial dose regimen of 5-10 mg twice daily. Two months later, the dose of ruxolitinib will be increased to 10-15 mg twice daily.
Trial: NCT03607955
Drug: AVB-S6-500
RxNorm normalized name: AVB-S6-500
DrugBank: Batiraxcept (DB17522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVB-S6-500 is supplied by Aravive Biologics
Trial: NCT03607955
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Commercially available
Trial: NCT03607955
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercially available